Anbio Biotechnology Payments to Acquire Marketable Securities
Anbio Biotechnology (NNNN) reported Payments to Acquire Marketable Securities of $35.47 million for the 12-month period ending 2024-12-31, per its 20-F filed 2025-04-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2025-04-28
| Period end | Payments to Acquire Marketable Securities 12 month |
|---|---|
| 2024-12-31 | $35.47M 20-F · filed 2025-04-28 |
| 2023-12-31 | $18.54M 20-F · filed 2025-04-28 |
| 2022-12-31 | $16.09M 20-F · filed 2025-04-28 |